Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
NCT01737710
Completed
Atopic dermatitis, also called eczema, is a disease in which the skin is dry and scaly with severe itching. People who have atopic dermatitis often have complications from skin infections; these can include eczema herpeticum after herpes simplex virus infection or eczema vaccinatum after smallpox vaccination. People with atopic dermatitis may suffer from skin infections and may therefore respond differently to vaccinations. A new flu vaccine which is injected into the skin instead of into muscl... Read More
Gender:
FEMALE
Ages:
Between 18 years and 64 years
Trial Updated:
02/27/2017
Locations: National Jewish Health, Denver, Colorado +4 locations
Conditions: Dermatitis, Atopic
Register for Updates
Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients
NCT00005009
Terminated
The purpose of this study is to find out whether Varivax is safe for use in children with kidney transplants and whether it protects children from serious infection. Varivax is a vaccine against varicella zoster virus (VZV), the virus that causes chickenpox (varicella) and shingles (zoster). Healthy children are already receiving Varivax shots to protect them from chickenpox. Few children with kidney transplants have received Varivax because doctors have been concerned that Varivax might cause... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
02/14/2017
Locations: University of Alabama at Birmingham - Vaccine and Treatment Evaluation Unit (VTEU), Birmingham, Alabama +3 locations
Conditions: Kidney Transplant Recipients
Register for Updates
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
NCT02214225
Completed
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and a trivalent influenza vaccine containing the alternate B strain (bioCSL TIV-2), in healthy adult volunteers aged 18 years and above.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2017
Locations: Site 296, Huntsville, Alabama +32 locations
Conditions: Influenza, Human
Register for Updates
Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
NCT02231957
Completed
There are a growing number of adolescents with chronic medical conditions in the United States. The Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination and annual influenza vaccination of all adolescents. Pneumococcal polysaccharide vaccination is also recommended for certain high-risk patients. Limited studies suggest that vaccination coverage of this population remains sub-optimal. Text message vaccine reminder/recall has been shown to be effective in increasing upta... Read More
Gender:
ALL
Ages:
11 years and above
Trial Updated:
01/27/2017
Locations: NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York
Conditions: Vaccination
Register for Updates
Efficacy of NicVAX in Smokers Who Want to Quit Smoking
NCT00318383
Completed
The purpose of this study is to determine whether vaccination with NicVAX will result in a higher continuous abstinence rate than vaccination with placebo in smokers who want to quit smoking. In addition, two different formulations and dosing schedules will be studied, to select the dose and dosing schedule which generates the highest level of anti-nicotine antibodies. The primary study period is 12 months, which was extended by amendment to include up to 2 years of observations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2017
Locations: David Geffen School of Medicine at UCLA, Los Angeles, California +8 locations
Conditions: Smoking Cessation
Register for Updates
An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
NCT00841477
Completed
The goal of the proposed study is to use the HBV vaccine as a model for a future HIV vaccine trial, examining the efficacy of community-based outreach intervention as well as an accelerated vaccine schedule as a method for increasing acceptance/adherence with HBV vaccination protocols among not-in-treatment drug users. This study will also examine the effect of HBV vaccination coupled with community-based outreach intervention on reducing the incidence of HIV, HBV and HCV infections and the freq... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2017
Locations: University of Texas-HSC at Houston, School of Public Health, Houston, Texas
Conditions: Hepatitis B Infection, Hepatitis C Infection, HIV Infection
Register for Updates
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT02040831
Completed
Respiratory syncytial virus (RSV) is a common cause of illness in infants and children around the world. This study will evaluate the safety and immune response to an RSV vaccine in RSV-seronegative infants and children. This study is a companion study to IMPAACT 2000.
Gender:
ALL
Ages:
Between 6 months and 24 months
Trial Updated:
12/20/2016
Locations: Center for Immunization Research, JHU, Baltimore, Maryland
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
NCT00503568
Completed
RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells. PURPOSE: This phase I trial is studying the effects of gp96-Ig vaccine therapy in treating patients with stage III, stage IV, or relapsed non-small cell lung cancer treated with first-line chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2016
Locations: University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Lung Cancer
Register for Updates
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
NCT02117570
Completed
This study will investigate a Clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine. The study will assess the safety and tolerability of the vaccine, and also look at the subjects' immune response to the vaccine.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
12/05/2016
Locations: Avail Clinical Research, LLC, DeLand, Florida +11 locations
Conditions: Clostridium Difficile Associated Disease
Register for Updates
Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents
NCT00297817
Completed
The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
11/30/2016
Locations: Not set, Encinitas, California +7 locations
Conditions: Meningococcal Disease
Register for Updates
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
NCT01246999
Completed
A total of 88 children between 2 and 9 years of age will be randomized to receive a two dose schedule of either licensed live attenuated trivalent seasonal influenza vaccine (LAIV) or licensed inactivated seasonal influenza vaccine (TIV)or TIV followed by LAIV or LAIV followed by TIV separated by 28 days. Children with a laboratory documented history of prior H1N1 infection will be excluded.
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
11/10/2016
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire +1 locations
Conditions: Influenza
Register for Updates
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
NCT02543918
Completed
The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with follow-up at 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/09/2016
Locations: Covance, Daytona Beach, Florida +2 locations
Conditions: Healthy
Register for Updates